Identification of a novel circ_0018289/miR-183-5p/TMED5 regulatory network in cervical cancer development

Heng Zou¹, Huijia Chen¹, Shuaibin Liu² and Xiaoling Gan²*

Abstract

Background: Circular RNAs (circRNAs) are increasingly implicated in regulating human carcinogenesis. Previous work showed the oncogenic activity of circ_0018289 in cervical cancer. However, the molecular basis underlying the modulation of circ_0018289 in cervical carcinogenesis is still not fully understood.

Methods: The levels of circ_0018289, microRNA (miR)-183-5p, and transmembrane p24 trafficking protein 5 (TMED5) were measured by quantitative real-time polymerase chain reaction (qRT-PCR) or western blot assay. Ribonuclease (RNase) R and subcellular localization assays were used to characterize circ_0018289. Cell proliferation was detected by the Cell Counting Kit-8 (CCK-8) and 5-ethyl-2′-deoxyuridine (Edu) assays. Cell apoptosis and tube formation were assessed by flow cytometry and tube formation assays, respectively. A dual-luciferase reporter assay was performed to confirm the direct relationship between miR-183-5p and circ_0018289 or TMED5. The role of circ_0018289 in tumor growth was gauged by mouse xenograft experiments.

Results: Circ_0018289 was overexpressed in cervical cancer tissues and cells. Circ_0018289 silencing impeded cell proliferation, enhanced cell apoptosis, and suppressed angiogenesis in vitro, as well as diminished tumor growth in vivo. Mechanistically, circ_0018289 targeted and regulated miR-183-5p by binding to miR-183-5p, and circ_0018289 regulated cervical cancer development and angiogenesis partially through miR-183-5p. Moreover, TMED5 was directly targeted and inhibited by miR-183-5p through the perfect complementary sites in TMED5 3′UTR, and TMED5 knockdown phenocopied miR-183-5p overexpression in suppressing cervical cancer development and angiogenesis. Furthermore, circ_0018289 induced TMED5 expression by competitively binding to shared miR-183-5p.

Conclusion: Our observations identified the circ_0018289/miR-183-5p/TMED5 regulatory network as a novel molecular basis underlying the modulation of cervical carcinogenesis.

Keywords: Cervical cancer, circ_0018289, miR-183-5p, TMED5, Angiogenesis

Introduction

Among women, cervical cancer ranks fourth for cancer mortality throughout the world [1]. Early-stage cervical cancer is curable, and more advanced tumors cannot be successfully treated despite the use of therapeutic methods that combine surgery and radiochemotherapy [2, 3]. Because the molecular determinants of cervical cancer are still not thoroughly understood, developing more effective therapies remains difficult. Hence, there is an urgent need to know the molecular basis of cervical carcinogenesis.

Covalently closed circular RNAs (circRNAs) are naturally occurring RNA biomolecules without 3′ polyadenylate tails or 5′ caps [4]. Insights into the potential...
functions of circRNAs on gene expression by inhibiting microRNA (miRNA) activity highlight their essential involvement in the biological basis of cancers, including cervical cancer [5–7]. For instance, Song et al. illuminated that circ_101996, an overexpressed circRNA in cervical cancer, worked as a strong promoter of the disease via miR-8075-dependent regulation of TPX2 microtubule nucleation factor [8]. Tang et al. uncovered that circ_0000515 contributed to cervical carcinogenesis by binding to miR-326 to induce ETS transcription factor ELK1 [9]. As for circ_0018289, generated from the exons of synaptotagmin 15 (SYT15) mRNA, it was demonstrated to be upregulated in cervical cancer, highlighting its potential as a promising biomarker for the outcome of patients [10]. Previous work also showed the oncogenic activity of circ_0018289 in cervical cancer depending on the modulation of miR-497 [11]. Nevertheless, our understanding of the molecular basis underlying the modulation of circ_0018289 in cervical carcinogenesis has remained incomplete.

Here, our data supported the tumor-promoting property of circ_0018289 in cervical cancer. We identified that circ_0018289 bound to miR-183-5p, a potent suppressor in cervical cancer [12, 13]. Furthermore, we demonstrated that the circ_0018289/miR-183-5p axis-mediated transmembrane p24 trafficking protein 5 (TMED5) expression impacted cervical carcinogenesis and angiogenesis.

Materials and methods
Bioinformatics
The putative miRNAs that directly bound to circ_0018289 in cervical cancer were searched by the computer algorithm circInteractome (https://circinteractome.nia.nih.gov/). MiRNA target prediction of human 3′untranslated region (3′UTR) transcripts was performed using the computational prediction software starBase (http://starbase.sysu.edu.cn/). Association between TMED5 level and the prognosis of cervical cancer patients was downloaded from the GEPIA database (http://gepia.cancer-pku.cn/).

Human samples and cells
Fresh-frozen samples of cervical cancer (n = 50) and matched normal cervical tissues (n = 50) were obtained with written informed consent from individuals undergoing cervical resection in the Second Affiliated Hospital of Chongqing Medical University. Samples were analyzed for the expression levels of circ_0018289, miR-183-5p, and TMED5. Approval to collect human samples was granted by the Ethical Committee of the Second Affiliated Hospital of Chongqing Medical University.

Human ectocervical Ect1/E6E7 cells, SiHa and HeLa cervical cancer cells, and human umbilical vein endothelial cells (HUVECs) were originally from American Type Culture Collection (ATCC, Manassas, VA, USA) and cultivated at 37 °C in 5% CO2 under standard conditions provided by ATCC. SiHa and HeLa cells were grown in EMEM with 10% FBS and 1% penicillin–streptomycin (all from Gibco, Tokyo, Japan). Ect1/E6E7 cells were cultured in serum-free keratinocyte medium with 0.05 mg/mL bovine pituitary extract, 0.1 ng/mL human recombinant EGF, 1% penicillin–streptomycin, and 0.4 mM calcium chloride (all from Gibco). HUVECs were maintained in F-12 K medium containing 10% FBS, 0.1 mg/mL Heparin, 0.05 mg/mL ECGs, and 1% penicillin–streptomycin (all from Gibco).

Plasmids
Human TMED5 (Accession: NM_001167830.2) coding sequence (lacking the 3′UTR region) incorporated with BamH I and EcoR V sites in two terminals and the scrambled control sequence were synthesized by BGI and individually inserted into the pcDNA3.1 vector (Invitrogen, Wesel, Germany) opened with BamH I and EcoR V sites to generate TMED5 overexpression plasmid (pcDNA-TMED5) and negative control (pcDNA). The fragments of human circ_0018289 and TMED5 3′UTR encompassing the target sequence for miR-183-5p or mutated target sites were synthesized by BGI and individually cloned into the 3′UTR of Renilla luciferase in a psiCHECK-2 vector (Promega, Milano, Italy) opened with Xho I and Pme I sites to generate luciferase reporter constructs.

Transient transfection of cells
SiHa and HeLa cells were plated at 5 × 10^5 cells/well in 24-well cell culture dishes 18 h before transfection with synthetic circ_0018289-selected siRNA (si-circ_0018289) or control shRNA (si-NC) at 100 nM, mature miR-183-5p mimic or mimic control (miRNA mimic) at 50 nM, or the antisense oligonucleotide of the mature miR-183-5p sequence designed to silence miRNA (anti-miR-183-5p) or nontarget control sequence (anti-miR-NC) at 50 nM using the HiPerFect transfection reagent as per the manufacturing recommendations (Qiagen, Tokyo, Japan). The details of all oligonucleotides (Ribobio, Guangzhou, China) were in Supplement Table 1. For TMED5 overexpression, 5 × 10^5 SiHa and HeLa cells seeded in each well of 24-well cell culture dishes were transiently transfected with pcDNA-TMED5 or pcDNA plasmid at a final dose of 200 ng using Lipofectamine 3000 as recommended by the manufacturers (Invitrogen). Transfected cells were collected for further assays 2 days post-transfection.
Quantitative real-time polymerase chain reaction (qRT-PCR)
Total RNA, inclusive of the small RNA fraction, was prepared from homogenized tissues and cultured cells with Trizol reagent as recommended by the manufacturers (Invitrogen). For circ_0018289 and mRNA quantification, cDNA was randomly primed with ReverTra Ace RT Kit (Toyobo, Tokyo, Japan) in a 25-μL reaction containing 500 ng of extracted RNA. qRT-PCR with iQ SYBR Green (Bio-Rad, Munich, Germany) and amplification primers (shown in Supplementary Table 1) was done on a PCR machine (Rotorgene 6000, Qiagen) with the following conditions: after a denaturation time of 10 min at 95 °C, 40 cycles at 95 °C for 20 s and at 60 °C for 1 min. For miR-183-5p quantification, cDNA preparation and qRT-PCR were carried out as above, using miScript RT Kit and SYBR Green Kit (all from Qiagen), respectively. Fold changes in gene and miRNA expression were determined by the $2^{-\Delta\Delta Ct}$ method, normalizing the results to normal controls and expression of β-actin or U6. ΔCt was calculated by subtracting the Ct values of β-actin or U6 from the Ct values of the gene of interest. ΔΔCt was then calculated by subtracting ΔCt value of the control from ΔCt of the sample.

Ribonuclease (RNase) R assay
This experiment was performed by incubating 3 μg of extracted RNA with 10 U of RNase R (Epicerent Biotechnologies, Madison, WI, USA) at 37 °C for 20 min. After being purified by the Trizol RNA Purification Kit (Invitrogen), RNA was analyzed by qRT-PCR analysis for quantification of circ_0018289 and SYT15 mRNA levels as above.

Subcellular localization assay
For the preparation of nuclear and cytoplasmic RNA of SiHa and HeLa cells, a Cytoplasmic and Nuclear RNA Purification Kit was used as described by the manufacturers (Norgen Biotek, Thorold, ON, Canada). For localization analysis, U6 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) served as the nuclear and cytoplasmic control, respectively. The isolated RNA was analyzed by qRT-PCR analysis for assessment of circ_0018289, U6, and GAPDH levels.

Cell proliferation assay
For the evaluation of cell proliferation, 5-ethynyl-2′-deoxyuridine (Edu) labeling and Cell Counting Kit-8 (CCK-8) assays were performed. Briefly, for Edu assay, transfected cells were incubated with Edu solution (50 μM, Ribobio) for 2 h, and subsequently, the Edu-labeled cells were stained with 1 × Apollo567 (Ribobio) for 30 min. After being staining with 4′,6-diamidino-2-phenylindole (DAPI, Invitrogen) for nuclei staining, the cells were observed under a BZ-8000 fluorescence microscope (Keyence, Osaka, Japan). The ratio of Edu-positive nuclei (red) to total nuclei (blue) was determined as the proliferation rate of transfected cells in 10 randomly captured fields per well. For CCK-8 assay, ~2500 transfected cells were plated into each well of 96-well cell culture dishes and incubated in complete medium at 37 °C. The cells were evaluated for potential growth every 24 h using the CCK-8 solution (10 μL per well) as per the manufacturing guidance (Dojindo, Kumamoto, Japan). After addition of CCK-8 solution, a 2-h incubation was allowed at 37 °C. A 96-well spectrometer (BMG Labtech, Ortenberg, Germany) was used to measure the absorption with a 450 nm filter.

Flow cytometry for cell apoptosis
Following the wash in cold phosphate-buffered saline (Solarbio, Beijing, China), transfected cells ($5 \times 10^5$) were incubated with propidium iodide (PI, 50 mg/mL, Invitrogen) and Annexin V–fluorescein isothiocyanate (10 μL, Annexin V-FITC, BD Pharmingen, Heidelberg, Germany) as per the accompanying protocols. Following a 15-min incubation in the dark, data were analyzed within 1 h using an Epics XL-MCL flow cytometer (Beckman Coulter, Fullerton, CA, USA) with FlowJo 9.1 software (Tree Star, Ashland, OR, USA). Apoptotic cells were defined as the population that was positive for Annexin.

Tube formation assay
Transfected cells ($1 \times 10^5$ cells per well) were seeded in 24-well cell culture dishes and incubated in complete medium at 37 °C. When the cells reached approximately 70% confluence, the complete medium was replaced by the serum-free EMEM medium. Following a 48-h culture at 37 °C, the conditional medium was harvested by centrifugation. Subsequently, about $2 \times 10^6$ HUVECs were suspended in 200 μL of the conditional medium and then plated in 24-well cell culture dishes precoated with Matrigel Basement Membrane Matrix (BD Biosciences, Cowley, UK). Images of tube morphology were photographed using an inverted 100× microscope (Keyence), and the tube formation was monitored every 6 h. The formed tubes were determined by counting the number of meshes using ImageJ software.

Western blot
Total protein was prepared from homogenized tissues and cultured cells using RIPA buffer (Solarbio) plus protease inhibitors (Roche, Mannheim, Germany) and quantified by the BCA method (Thermo Fisher Scientific, Monza, Italy), Immunoblots were carried out with
the isolated protein as described [14]. Equal amounts of protein were resolved by electrophoresis on Criterion™ TGX™ precast 10% gels (Bio-Rad), transferred to nitrocellulose membranes (BD Biosciences), and probed with antibodies against B cell lymphoma-2 (Bcl-2, ab182858, dilution 1:2000), vascular endothelial growth factor A (VEGFA, ab1316, dilution 1:1000), fibroblast growth factor 2 (FGF2, ab92337, dilution 1:3000), Bcl-2 associated X (Bax, ab182733, dilution 1:2000), TMED5 (ab254795, dilution 1:1000), and β-actin (ab8227, dilution 1:3000) from Abcam (Cambridge, UK). The horseradish peroxidase-conjugated IgG (ab205718, dilution 1:5000, Abcam) was used as the secondary antibody. Chemiluminescence was achieved by the incubation of Clarity ECL substrate (Bio-Rad). Protein blots were scanned and quantified using AIDA software (Raytek, Sheffield, UK).

**Dual-luciferase reporter assay**

 Luciferase reporter constructs (200 ng) were transfected using Lipofectamine 3000 into SiHa and HeLa cells seed in 24-well cell culture dishes (5 × 10^5 cells/well) together with synthetic miR-183-5p mimic or control mimic at 50 nM. Luciferase activity was gauged after 2 days using a 10 μL of cell lysates with the Luc-Pair miR Luciferase Assay Kit (GeneCopoeia, Rockville, MD, USA) on a luminometer (Promega) as per the accompanying guidance.

**Generation of stable circ_0018289 silencing cell line**

 Lenti-viruses expressing shRNA-circ_0018289 (sh-circ_0018289) or scrambled shRNA (sh-NC) were provided by Geneseed (Guangzhou, China) and used to infect SiHa cells in media containing polybrene (8 μg/mL, Solarbio). A stable cell line was selected using 2 mg/mL of puromycin for over 7 days.

**Mouse xenograft experiments**

 All experiments with mice conformed to the protocols approved by the Animal Use Committee of the Second Affiliated Hospital of Chongqing Medical University, and all mice were cared following National Institutes of Health guidelines. For the formation of xenograft tumors, 4- to 5-week-old female BALB/c nude mice (Gepharma-tech Biotechnology Co., Ltd., Jiangsu, China) were implanted subcutaneously with sh-NC- or sh-circ_0018289-transduced SiHa cells (5 × 10^6 cells per mouse) in 200 μL of cell culture medium (n = 6 mice per group). Tumor growth was monitored weekly by caliper measurements and tumor volume was determined by the equation \( V = \frac{4}{3} \pi \times d^3 / 2 \), where \( D \) was the longest diameter of the tumor and \( d \) was the shortest diameter. Mice were sacrificed at day 35 after cell implantation with CO₂ overdose and the tumors were harvested for weight and expression analysis. Proliferation of tumors was evaluated with paraffin embedded tumor sections (4 μm) by immuno-histochemistry using a monoclonal antibody against Ki67 (ab16667, Abcam, dilution 1:200), Vectastain ABC Kit (Vector Laboratories, Burlingame, CA, USA), and 3,3′-diaminobenzidine (DAB) substrate (Vector Laboratories) as described [15].

**Statistical analysis**

 For descriptive statistics, data were presented as mean ± standard derivation from at least 3 independent biological replicates (performed in quadruplicate). Statistical analysis was done on the Prism 7 software (GraphPad, San Diego, CA, USA). P values were determined by Student’s two-tailed t-test (comparison in two groups), Mann–Whitney U test (comparison in human samples), or one-way analysis of variance with Tukey–Kramer multiple comparison test (comparison in multiple groups), with \( P < 0.05 \) accepting significance. The Pearson’s correlation coefficients were used to determine the correlations among circ_0018289, miR-183-5p, and TMED5 expression levels in human tumors.

**Results**

**Circ_0018289 was overexpressed in cervical cancer**

 To evaluate the role of circ_0018289 in cervical cancer, we firstly analyzed its expression in 50 primary tumor samples by qRT-PCR analysis. Circ_0018289 was markedly upregulated in tumor samples compared with paired normal tissues (Fig. 1A). In agreement with tumor samples, cancer cells showed higher levels of circ_0018289 compared to ectocervical Ect1/E6E7 cells (Fig. 1B). We then determined the stability of circ_0018289 in SiHa and HeLa cells by RNase R assay. Circ_0018289, rather than the corresponding linear SYT15 mRNA, was resistant to RNase R (Fig. 1C). Furthermore, circ_0018289 was mainly present in the cytoplasm of SiHa and HeLa cells, which was confirmed by subcellular localization assay (Fig. 1D).

**Circ_0018289 silencing impeded cell proliferation and enhanced cell apoptosis in vitro**

 To elucidate the functional action of circ_0018289 in cervical carcinogenesis, we used siRNA-circ_0018289 (si-circ_0018289) in SiHa and HeLa cells to knock down its expression (Fig. 2A). As expected, si-circ_0018289 transfection inhibited circ_0018289 expression by > twofold (Fig. 2A). Analyses of CCK-8 and Edu showed that circ_0018289 loss of function remarkably impeded cell proliferation (Fig. 2B, C). Conversely, silencing endogenous circ_0018289 promoted cell apoptosis (Fig. 2D). Additionally, western blot analysis revealed that circ_0018289 knockdown increased pro-apoptotic protein Bax level and reduced
anti-apoptotic protein Bcl-2 expression in both cell lines (Fig. 2E), reinforcing that circ_0018289 loss of function enhanced apoptosis.

Circ_0018289 silencing suppressed angiogenesis in vitro

We next examined the influence of silencing endogenous circ_0018289 on angiogenesis in vitro. We firstly transfected SiHa and HeLa cells with si-circ_0018289 or nontarget-shRNA (si-NC) and then treated human HUVECs with the conditional medium of transfected cells. Strikingly, the incubation of conditional medium of cells with circ_0018289 loss of function led to an inhibition of tube formation of HUVECs (Fig. 2F), demonstrating that circ_0018289 silencing suppressed angiogenesis in vitro. Additionally, circ_0018289 knockdown decreased the levels of angiogenesis inducers VEGFA and FGF2 in the two cancer cell lines (Fig. 2G).

Circ_0018289 directly targeted miR-183-5p

To further elucidate the mechanism by which circ_0018289 regulated cervical carcinogenesis and angiogenesis, we identified its targeted miRNAs. Computer algorithm circInteractome predicted that circ_0018289 harbored a region that was partially complementary to miR-183-5p (Fig. 3A). To verify this finding, we cloned circ_0018289 segment containing the seed sequence into a luciferase vector and cotransfected the reporter into SiHa and HeLa cells with miR-183-5p mimic. The transfection efficiency of miR-183-5p mimic was examined by qRT-PCR (Fig. 3B). Remarkably,
Fig. 2 (See legend on previous page.)
the reporter construct with the binding sites for miR-183-5p was repressed by miR-183-5p overexpression (Fig. 3C). We then generated a mutant in the binding sequence (Fig. 3A) and tested it. As expected, the mutant encompassing a mutated binding region was refractory to repression of miR-183-5p (Fig. 3C). Moreover, we observed a clear augmentation (> two-fold) in the level of the endogenous miR-183-5p in circ_0018289-silencing cells (Fig. 3D). Contrary to the level of circ_0018289, miR-183-5p was markedly underexpressed in tumor samples and cancer cells compared with their counterparts (Fig. 3E, F). Intriguingly, there existed an inverse correlation between miR-183-5p and circ_0018289 levels in tumor samples (Fig. 3G). These data together indicated that circ_0018289 targeted miR-183-5p by directly binding to miR-183-5p.

**MiR-183-5p mediated the regulation of circ_0018289 in cervical cancer development and angiogenesis in vitro**

We next investigated whether circ_0018289 regulated cervical carcinogenesis and angiogenesis by miR-183-5p. The transfection efficiency of anti-miR-183-5p in SiHa and HeLa cells was confirmed by qRT-PCR (Fig. 4A). As expected, the transfection of anti-miR-183-5p in SiHa and HeLa cells resulted in a significant suppression of circ_0018289 silencing (Fig. 4B, C) and proliferation suppression (Fig. 4D, E). Moreover, miR-183-5p depletion abolished the inhibition of circ_0018289 silencing on tube formation of HUVECs (Fig. 4F). Additionally, the deficiency of miR-183-5p counteracted the suppression of VEGFA and FGF2 expression of circ_0018289 knockdown in both SiHa and HeLa cell lines (Fig. 4G).
TMED5 was directly targeted and inhibited by miR-183-5p
To identify downstream targets of miR-183-5p, we used computational prediction software starBase. Interestingly, a putative binding region for miR-183-5p was found in the 3'UTR of TMED5 (Fig. 5A), which was shown to be associated with the prognosis of cervical cancer patients using the GEPIA database (http://gepia.cancer-pku.cn/, Fig. 5B). To establish the direct relationship between TMED5 and miR-183-5p, we generated TMED5 3'UTR wild-type (TMED5 3'UTR-WT) and mutant (TMED5 3'UTR-MUT) reporter constructs and analyzed them by dual-luciferase reporter assays. Overexpression of miR-183-5p by miR-183-5p mimic transfection remarkably repressed reporter gene expression of TMED5 3'UTR-WT, and the mutation abrogated the suppression of miR-183-5p (Fig. 5C). Moreover, endogenous TMED5 mRNA and protein levels were strongly promoted by miR-183-5p depletion and inhibited as a result of miR-183-5p overexpression in the two cancer cell lines (Fig. 5D, E). Analysis of TMED5 expression in cervical cancer showed that TMED5 mRNA and protein levels were significantly promoted in tumor samples and cancer cells compared with the corresponding normal controls (Fig. 5F–I). Importantly, TMED5 mRNA level inversely correlated with miR-183-5p expression and positively correlated with circ_0018289 expression in tumor samples (Fig. 5J, K). All these data established the notion that miR-183-5p regulated TMED5 expression by the perfect binding sites in the 3'UTR.

MiR-183-5p-mediated inhibition of TMED5 impacted cervical cancer development and angiogenesis in vitro
In order to demonstrate whether inhibition of TMED5 by miR-183-5p was responsible for the regulatory effects of miR-183-5p on cervical carcinogenesis and angiogenesis, we adopted a rescue experiment by increasing TMED5 expression in SiHa and HeLa cells. The transfection efficiency of TMED5 overexpression plasmid (pcDNA-TMED5) was gauged by qRT-PCR and western blot assays (Fig. 6A, B). As would be expected, elevated expression of TMED5 significantly abrogated miR-183-5p overexpression-mediated anti-proliferation (Fig. 6C, D) and pro-apoptosis (Fig. 6E, F) effects in the
two cancer cell lines. Furthermore, elevated expression of TMED5 reversed the suppression of tube formation of miR-183-5p overexpression in HUVECs (Fig. 6G). Additionally, elevated expression of TMED5 abrogated miR-183-5p overexpression-mediated inhibition on VEGFA and FGF2 levels in both SiHa and HeLa cell line (Fig. 6H).

Circ_0018289 regulated TMED5 expression by targeting miR-183-5p

Next, we asked whether circ_0018289 could operate as a regulator of TMED5. Notably, circ_0018289 loss of function resulted in reduced levels of TMED5 mRNA and protein in SiHa and HeLa cells (Fig. 7A, B). However, this effect was remarkably abolished by miR-183-5p depletion (Fig. 7A, B).

Circ_0018289 silencing diminished tumor growth in vivo

To determine whether circ_0018289 silencing possessed tumor-inhibitory effects, we reduced circ_0018289 expression with a lentiviral delivery system (sh-circ_0018289) in SiHa cells and then implanted the cells subcutaneously in the nude mice. By contrast, transduction with sh-circ_0018289 led to markedly decreased
volume and weight of the tumors (Fig. 8A, B). Moreover, the tumors formed by sh-circ_0018289-transduced SiHa cells exhibited lower levels of circ_0018289 compared with the controls (Fig. 8C). qRT-PCR and western blot analyses of the tumors showed that circ_0018289 silencing resulted in increased expression of miR-183-5p (Fig. 8D) and reduced levels of TMED5 mRNA and protein (Fig. 8E, F). Additionally, tumor-inhibitory result of circ_0018289 silencing was also confirmed by staining for cell proliferation using the cell-cycle marker
Ki67 (Fig. 8G). These results together suggested that the inhibition of tumor growth might be due to downregulation of circ_0018289 and TMED5 and upregulation of miR-183-5p.

Discussion

CircRNAs are increasingly implicated in regulating human carcinogenesis [16–18]. Previous work uncovered the overexpression and tumor-promoting activity of circ_0018289 in cervical cancer [10, 11]. We here extended these findings by identifying a novel circ_0018289/miR-183-5p/TMED5 regulatory network in cervical cancer development. Taken together, we proposed that circ_0018289 might be a potent oncogene in cervical tumorigenesis. As previously reported for other circRNAs [19, 20], circ_0018289 was resistant to RNase R due to the back-spliced formation and the lack of 3′ and 5′ ends [4]. Additionally, circ_0018289 was mainly present in the cytoplasm, providing the possibility for its relationship with mature miRNAs [21].

Emerging evidence has suggested that alterations in miRNA expression might prove crucial in affecting cervical tumorigenesis [22–24]. Here, we focused on miR-183-5p because of the conflicting roles of miR-183-5p in human carcinogenesis [25–27]. These contradictory conclusions might partially due to the different types of tumors in these reports, where miR-183-5p facilitated the development of breast cancer [26] and hepatocellular carcinoma [27] and impeded endometrial tumorigenesis [25]. Here, we first elucidated that circ_0018289 directly targeted miR-183-5p, which was established as a strong suppressor in cervical cancer [12, 13]. Our data also showed the regulation of circ_0018289 in cervical cancer development and angiogenesis through miR-183-5p.
TMED5, located at chromosomal region 1p21-22, was associated with the pathogenesis of myeloma and bladder cancer [28, 29]. A previous study uncovered the tumor-promoting effect of TMED5 on the malignant development of cervical cancer by activating the Wnt7b/b-catenin signaling pathway [30]. Our results identified that TMED5 was directly targeted and inhibited by miR-183-5p, and TMED5 knockdown phenocopied miR-183-5p over-expression in suppressing cervical cancer development and angiogenesis. Importantly, we highlighted that circ_0018289 induced TMED5 expression by binding to miR-183-5p. Furthermore, our data showed that the circ_0018289/miR-183-5p/TMED5 axis contributed to an elevated expression of VEGFA and FGF2, two angiogenesis inducers [31, 32], leading to induction of tumor-associated angiogenesis. Additionally, in vivo assays implied the involvement of the circ_0018289/miR-183-5p/TMED5 regulatory network in tumor growth, and the direct evidence should be further elucidated in further work.

Conclusions
Taken together, our findings identified a novel molecular basis, circ_0018289/miR-183-5p/TMED5 regulatory network, underlying the modulation of cervical carcinogenesis. These observations suggested that circ_0018289 inhibition might be a promising point for the development of novel anti-tumor strategies against cervical cancer.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12957-021-02350-y.

Additional file 1: Supplement Table 1. Sequences of qRT-PCR primers and oligonucleotides.

Acknowledgements
None.

Authors’ contributions
Heng Zou designed and performed the research; Huijia Chen, Shuaibin Liu and Xiaoling Gan analyzed the data; Heng Zou wrote the manuscript. All authors read and approved the final manuscript.

Funding
None.

Availability of data and materials
Not applicable.

Declarations
Ethics approval and consent to participate
Written informed consents were obtained from all participants and this study was permitted by the Ethics Committee of the Second Affiliated Hospital of Chongqing Medical University.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no conflict of interest.

Author details
1 The Center for Reproductive Medicine, Obstetrics and Gynecology Department, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China. 2 Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Chongqing Medical University, No.74 Linjiang Road, Yuzhong District, Chongqing 400010, China.

Received: 18 June 2021 Accepted: 27 July 2021

Published online: 17 August 2021

References
1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
2. Wuehrthner BA, Avila-Wallace M. Cervical cancer: screening, management, and prevention. Nurse Pract. 2016;41(9):18–23.
3. Vu M, Yu J, Avololde OA, et al. Cervical cancer worldwide. Curr Probl Cancer. 2018;42(5):457–65.
4. Kristensen LS, Andersen MS, Stagsted LVW, et al. The biogenesis, biology and characterization of circular RNAs. Nat Rev Genet. 2019;20(11):675–91.
5. Chaichian S, Shafabakhsh R, Mirmashemi SM, et al. Circular RNAs: a novel biomarker for cervical cancer. J Cell Physiol. 2020;235(2):718–24.
6. Xu T, Song X, Wang Y, et al. Genome-wide analysis of the expression of circular RNA full-length transcripts and construction of the circrNA-miRNA-miRNA network in cervical cancer. Front Cell Dev Biol. 2020;8:603516.
7. Yi Y, Liu Y, Wu W, et al. Reconstruction and analysis of circRNA-miRNA-miRNA network in the pathology of cervical cancer. Oncol Rep. 2019;41(4):2209–25.
8. Song T, Xu A, Zhang Z, et al. CircRNA hsa_circRNA_101996 increases cervical cancer proliferation and invasion through activating TPM2 expression by restraining miR-807. J Cell Physiol. 2019;234(8):14296–305.
9. Tang Q, Chen Z, Zhao L, et al. Circular RNA hsa_circ_0000515 acts as a miR-326 sponge to promote cervical cancer progression through up-regulation of ELK1. Aging (Albany NY). 2019;11(22):9982–99.
10. He J, Lv X, Zeng Z. A potential disease monitoring and prognostic biomarker in cervical cancer patients: the clinical application of circular RNA_0018289. J Clin Lab Anal. 2020;34(8):e23340.
11. Gao YL, Zhang MY, Xu B, et al. Circular RNA expression profiles reveal that hsa_circ_0018289 is up-regulated in cervical cancer and promotes the tumorigenesis. Oncotarget. 2017;8(49):86625–33.
12. Zhang W, Zhang M, Liu L, et al. MicroRNA-183-5p inhibits aggressiveness of cervical cancer cells by targeting integrin subunit beta 1 (ITGB1). Med Sci Monit. 2018;24:7137–45.
13. Tang Q, Liu L, Zhang H, et al. Regulations of miR-183-5p and Snail-mediated Shikimic-reduced epithelial-mesenchymal transition in cervical cancer cells. Drug Des Devel Ther. 2020;14:577–89.
14. D’Souza A, Pearman CM, Wang Y, et al. Targeting miR-423-5p reverses exercise training-induced HCN4 channel remodeling and sinus bradycardia. Res Biol Sci. 2017;121(9):1058–68.
15. Hatley ME, Patrick DM, Garcia MR, et al. Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell. 2010;18(3):282–93.
16. Kristensen LS, Hansen TB, Venø MT, et al. Circular RNAs in cancer: opportunities and challenges in the field. Oncogene. 2018;37(5):555–65.
17. Liu R, Deng P, Zhang Y, et al. CircRNA_0082182 promotes oncogenesis and metastasis of colorectal cancer in vitro and in vivo by sponging miR-411 and miR-1205 to activate the Wnt/b-catenin pathway. World J Surg Oncol. 2021;19(1):51.
18. Liu Y, Li H, Ye X, et al. Hsa_circ_0000231 knockdown inhibits the glycolysis and progression of colorectal cancer cells by regulating miR-502-5p/ MYO6 axis. World J Surg Oncol. 2020;18(1):255.
19. Li M, Deng W, Tariq MA, et al. A circular transcript of ncST1 gene mediates ischemic myocardial injury by targeting miR-133a-3p. Theranostics. 2018;8(21):5855–69.
20. Zheng X, Chen L, Zhou Y, et al. A novel protein encoded by a circular RNA circPPP1R12A promotes tumor pathogenesis and metastasis of colon cancer via Hippo-YAP signaling. Mol Cancer. 2019;18(1):47.
21. Iwakawa HO, Tomari Y. The functions of microRNAs: mRNA decay and translational repression. Trends Cell Biol. 2015;25(11):651–65.
22. Lee H, Kim KR, Cho NH, et al. MicroRNA expression profiling and Notch1 and Notch2 expression in minimal deviation adenocarcinoma of uterine cervix. World J Surg Oncol. 2014;12:334.
23. Fu K, Zhang L, Liu R, et al. MiR-125 inhibited cervical cancer progression by regulating VEGF and PI3K/AKT signaling pathway. World J Surg Oncol. 2020;18(1):115.
24. Zhu L, Tu H, Liang Y, et al. MiR-218 produces anti-tumor effects on cervical cancer cells in vitro. World J Surg Oncol. 2018;16(1):204.
25. Yan H, Sun BM, Zhang YY, et al. Upregulation of miR-183-5p is responsible for the promotion of apoptosis and inhibition of the epithelial-mesenchymal transition, proliferation, invasion and migration of human endometrial cancer cells by downregulating Ezrin. Int J Mol Med. 2018;42(5):2469–80.
26. Li Y, Zeng Q, Qiu J, et al. MiR-183-5p promotes proliferation, metastasis and angiogenesis in breast cancer cells through negatively regulating four and a half LIM protein 1. J Breast Cancer. 2020;23(4):355–72.
27. Yan R, Li K, Yuan D, et al. MiR-183-5p promotes proliferation and migration in hepatocellular carcinoma by targeting IRS1 and its association with patient survival. Int J Biol Markers. 2020;35(3):83–9.
28. Boyd KD, Ross FM, Walker BA, et al. Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival. Clin Cancer Res. 2011;17(24):7776–84.
29. Scaravilli M, Asero P, Tammela TL, et al. Mapping of the chromosomal amplification 1p21-22 in bladder cancer. BMC Res Notes. 2014;7:547.
30. Yang Z, Sun Q, Guo J, et al. GRSF1-mediated MiR-G-1 promotes malignant behavior and nuclear autophagy by directly upregulating TMED5 and LMNB1 in cervical cancer cells. Autophagy. 2019;15(4):668–85.
31. Claesson-Welsh L, Welsh M. VEGFA and tumour angiogenesis. J Intern Med. 2013;273(2):114–27.
32. Mori S, Hatori N, Kawaguchi N, et al. The integrin-binding defective FGF2 mutants potently suppress FGF2 signalling and angiogenesis. Biosci Rep. 2017;37(2):BSR20170173.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.